1. Оковитый С.В., Гайворонская В.В., Куликов А.Н., Шуленин С.Н. Клиническая фармакология: избранные лекции. М., 2009.
2. Соловьева Э.Ю. Терапевтические подходы к лечению атеротромбоза. Справ. поликлин. врача. 2014; 5.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308 (6921): 81–106.
4. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.
5. De Schryver E, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006; 2: CD001820.
6. Halkes P, van Gijn J, Kappelle L et al. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006; 367 (9523): 1665–73.
7. Lip G, Kamath S, Hart R. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ 2002; 325: 1161–3.
8. Mees S, Rinkel G, Hop J еt al. Antiplatelet Therapy in Aneurysmal Subarachnoid Hemorrhage. Syst Rev Stroke 2003; 34: 2285–9.